Bausch Health Companies Inc (NYSE:BHC) – Equities research analysts at Piper Jaffray Companies boosted their Q2 2019 earnings per share estimates for shares of Bausch Health Companies in a report issued on Wednesday, February 20th. Piper Jaffray Companies analyst D. Amsellem now expects that the company will post earnings of $1.00 per share for the quarter, up from their prior estimate of $0.97. Piper Jaffray Companies currently has a “Overweight” rating and a $27.00 target price on the stock. Piper Jaffray Companies also issued estimates for Bausch Health Companies’ Q4 2019 earnings at $1.12 EPS, FY2020 earnings at $4.28 EPS and FY2021 earnings at $4.76 EPS.
Bausch Health Companies (NYSE:BHC) last announced its earnings results on Wednesday, February 20th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The business had revenue of $2.12 billion for the quarter, compared to analysts’ expectations of $2.08 billion. Bausch Health Companies had a positive return on equity of 37.37% and a negative net margin of 50.83%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.98 earnings per share.
Several other research analysts have also recently issued reports on BHC. Zacks Investment Research raised Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Tuesday, January 29th. ValuEngine raised Bausch Health Companies from a “sell” rating to a “hold” rating in a research note on Tuesday, November 6th. Royal Bank of Canada raised their price objective on Bausch Health Companies from $30.00 to $31.00 and gave the stock a “hold” rating in a research note on Wednesday, November 7th. Wells Fargo & Co raised their price objective on Bausch Health Companies from $9.00 to $25.19 and gave the stock an “underperform” rating in a research note on Tuesday. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Bausch Health Companies in a research note on Tuesday, November 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. Bausch Health Companies currently has an average rating of “Hold” and an average target price of $27.61.
Shares of NYSE:BHC opened at $23.75 on Friday. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 5.91, a PEG ratio of 0.31 and a beta of 0.63. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.91 and a current ratio of 1.14. Bausch Health Companies has a 52-week low of $14.44 and a 52-week high of $28.45.
In related news, insider Thomas Appio acquired 25,440 shares of the firm’s stock in a transaction dated Friday, December 14th. The shares were purchased at an average price of $22.96 per share, with a total value of $584,102.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.54% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. ValueAct Holdings L.P. bought a new stake in Bausch Health Companies in the 3rd quarter worth approximately $462,911,000. Vanguard Group Inc. bought a new stake in Bausch Health Companies in the 3rd quarter worth approximately $223,173,000. Vanguard Group Inc bought a new stake in Bausch Health Companies in the 3rd quarter worth approximately $223,173,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Bausch Health Companies by 0.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock worth $156,267,000 after acquiring an additional 75,175 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Bausch Health Companies in the 3rd quarter worth approximately $135,538,000. 50.63% of the stock is currently owned by institutional investors.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Read More: How mutual funds make money
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.